
Cooper Companies (COO) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Apr 2025Income Metrics
Revenue
1.0B
Gross Profit
679.1M
67.75%
Operating Income
184.8M
18.44%
Net Income
87.7M
8.75%
EPS (Diluted)
$0.44
Balance Sheet Metrics
Total Assets
12.4B
Total Liabilities
4.1B
Shareholders Equity
8.3B
Debt to Equity
0.50
Cash Flow Metrics
Operating Cash Flow
261.8M
Free Cash Flow
18.1M
Revenue & Profitability Trend
Cooper Companies Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 3.9B | 3.6B | 3.3B | 2.9B | 2.4B |
Cost of Goods Sold | 1.3B | 1.2B | 1.2B | 966.7M | 896.1M |
Gross Profit | 2.6B | 2.4B | 2.1B | 2.0B | 1.5B |
Gross Margin % | 66.6% | 65.6% | 64.7% | 66.9% | 63.1% |
Operating Expenses | |||||
Research & Development | 155.1M | 137.4M | 110.3M | 92.7M | 93.3M |
Selling, General & Administrative | 1.5B | 1.5B | 1.3B | 1.2B | 992.5M |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 1.7B | 1.6B | 1.5B | 1.3B | 1.1B |
Operating Income | 705.7M | 533.1M | 507.6M | 505.8M | 311.8M |
Operating Margin % | 18.1% | 14.8% | 15.3% | 17.3% | 12.8% |
Non-Operating Items | |||||
Interest Income | - | - | - | - | - |
Interest Expense | 114.3M | 105.3M | 57.3M | 23.1M | 36.8M |
Other Non-Operating Income | -9.1M | -14.9M | 25.0M | 8.8M | -8.5M |
Pre-tax Income | 582.3M | 412.9M | 475.3M | 491.5M | 266.5M |
Income Tax | 190.0M | 118.7M | 89.5M | -2.5B | 28.1M |
Effective Tax Rate % | 32.6% | 28.7% | 18.8% | -499.1% | 10.5% |
Net Income | 392.3M | 294.2M | 385.8M | 2.9B | 238.4M |
Net Margin % | 10.1% | 8.2% | 11.7% | 100.8% | 9.8% |
Key Metrics | |||||
EBITDA | 1.1B | 892.9M | 878.7M | 823.9M | 590.4M |
EPS (Basic) | $1.97 | $1.49 | $1.95 | $14.93 | $1.21 |
EPS (Diluted) | $1.96 | $1.48 | $1.94 | $14.79 | $1.20 |
Basic Shares Outstanding | 199600000 | 197900000 | 197400000 | 197200000 | 196400000 |
Diluted Shares Outstanding | 199600000 | 197900000 | 197400000 | 197200000 | 196400000 |
Income Statement Trend
Cooper Companies Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 107.6M | 120.8M | 138.2M | 95.9M | 115.9M |
Short-term Investments | - | - | - | - | - |
Accounts Receivable | 717.0M | 609.7M | 557.8M | 515.3M | 435.4M |
Inventory | 802.7M | 735.6M | 628.7M | 585.6M | 570.4M |
Other Current Assets | 324.2M | 238.8M | 208.9M | 179.3M | 152.5M |
Total Current Assets | 2.0B | 1.7B | 1.5B | 1.5B | 1.3B |
Non-Current Assets | |||||
Property, Plant & Equipment | 2.9M | 3.8M | 19.2M | 257.0M | 260.2M |
Goodwill | 9.5B | 9.0B | 9.1B | 6.4B | 6.2B |
Intangible Assets | 1.8B | 1.7B | 1.9B | 1.3B | 1.3B |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 2.9B | 3.0B | 3.0B | 2.9B | 184.9M |
Total Non-Current Assets | 10.4B | 10.0B | 10.0B | 8.1B | 5.5B |
Total Assets | 12.3B | 11.7B | 11.5B | 9.6B | 6.7B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 260.5M | 261.9M | 248.8M | 161.4M | 176.0M |
Short-term Debt | 33.3M | 45.4M | 412.6M | 83.4M | 442.6M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 424.3M | 363.3M | 373.1M | 319.6M | 266.8M |
Total Current Liabilities | 1.0B | 969.0M | 1.3B | 732.1M | 1.0B |
Non-Current Liabilities | |||||
Long-term Debt | 2.6B | 2.5B | 2.4B | 1.4B | 1.6B |
Deferred Tax Liabilities | 96.0M | 101.5M | 149.9M | 24.1M | 25.8M |
Other Non-Current Liabilities | 311.6M | 239.2M | 225.2M | - | - |
Total Non-Current Liabilities | 3.2B | 3.1B | 3.0B | 1.9B | 1.9B |
Total Liabilities | 4.2B | 4.1B | 4.3B | 2.7B | 2.9B |
Equity | |||||
Common Stock | 21.7M | 21.6M | 5.4M | 5.4M | 5.3M |
Retained Earnings | 7.3B | 6.9B | 6.6B | 6.2B | 3.3B |
Treasury Stock | 706.0M | 710.3M | 714.5M | 639.6M | 617.3M |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 8.1B | 7.6B | 7.2B | 6.9B | 3.8B |
Key Metrics | |||||
Total Debt | 2.6B | 2.6B | 2.8B | 1.5B | 2.1B |
Working Capital | 928.7M | 735.9M | 253.4M | 733.2M | 269.8M |
Balance Sheet Composition
Cooper Companies Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 392.3M | 294.2M | 385.8M | 2.9B | 238.4M |
Depreciation & Amortization | 375.1M | 367.7M | 346.1M | 309.3M | 287.1M |
Stock-Based Compensation | 75.1M | 62.1M | 54.2M | 43.8M | 37.6M |
Working Capital Changes | -321.9M | -290.1M | -179.0M | -219.0M | -104.1M |
Operating Cash Flow | 678.2M | 486.8M | 682.9M | 674.5M | 490.6M |
Investing Activities | |||||
Capital Expenditures | -421.2M | -392.5M | -242.0M | -214.4M | -310.4M |
Acquisitions | -343.4M | -56.5M | -1.6B | -235.9M | -54.1M |
Investment Purchases | - | - | - | - | - |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | -764.6M | -449.0M | -1.8B | -450.3M | -364.5M |
Financing Activities | |||||
Share Repurchases | 0 | 0 | -78.5M | -24.8M | -47.8M |
Dividends Paid | 0 | -3.0M | -3.0M | -3.0M | -3.0M |
Debt Issuance | 3.5B | 2.1B | 1.5B | 1.4B | 3.2B |
Debt Repayment | -3.5B | -2.0B | -561.5M | -1.4B | -3.2B |
Financing Cash Flow | 5.6M | -183.8M | 1.2B | -337.8M | -94.9M |
Free Cash Flow | 288.1M | 215.0M | 450.4M | 524.2M | 176.2M |
Net Change in Cash | -80.8M | -146.0M | 46.1M | -113.6M | 31.2M |
Cash Flow Trend
Cooper Companies Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
35.39
Forward P/E
17.96
Price to Book
1.76
Price to Sales
3.66
PEG Ratio
-19.97
Profitability Ratios
Profit Margin
10.39%
Operating Margin
18.44%
Return on Equity
5.15%
Return on Assets
3.88%
Financial Health
Current Ratio
2.10
Debt to Equity
31.19
Beta
1.00
Per Share Data
EPS (TTM)
$2.07
Book Value per Share
$41.54
Revenue per Share
$19.99
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
coo | 14.6B | 35.39 | 1.76 | 5.15% | 10.39% | 31.19 |
Intuitive Surgical | 171.8B | 66.65 | 9.62 | 16.04% | 28.51% | 0.00 |
Becton, Dickinson | 56.3B | 35.89 | 2.21 | 6.18% | 7.41% | 75.93 |
Alcon | 45.8B | 40.84 | 2.07 | 5.23% | 11.28% | 23.63 |
ResMed | 41.9B | 30.11 | 7.02 | 25.86% | 27.22% | 14.27 |
West Pharmaceutical | 17.8B | 36.97 | 6.06 | 17.72% | 16.48% | 10.52 |
Financial data is updated regularly. All figures are in the company's reporting currency.